CMIC CMO USA, Cranbury, NJ – April 16, 2018 — CMIC Group, the largest CRO in Japan with end to end Pharmaceutical Value Creator solutions, announced today that its US subsidiary (Booth #1252) technical experts will present novel Rotor/GXR technology for oral solid drug development and join a panel discussion on small molecule drug development at this week’s Interphex Conference at Javits Center, New York City.


Application of Rotor/GXR Technology for Development of Oral Solid Products

On Tuesday, April 17 1:30pm -2:15 pm, Dr. Guihua Qian, Associate Director, Technical Service, will present “Application of Rotor/GXR Technology for Development of Oral Solid Products” at PBOA CMO/CDMO Theater. The novel Rotor/GXR technology has many advantages such as handling relative small size powder, taking relative less process time, and it can be widely used for pellet / powder process.

Dr. Qian has more than 18 years of pharmaceutical industry experiences working on drug product development and commercialization. Before Joining CMIC, he has worked for more than 4 years at Catalent Pharma Solutions, responsible for oral solid formulation and process development. Prior to Catalent, Dr. Qian also worked as development scientist for formulation and process development in J&J and Elan Pharmaceuticals.


Small Molecule Drug Development Business Trend

On Tuesday, April 17 3:30pm -4:15 pm, Michael Odonoghue,  Sr. Director, Operation and Board of Director, CMIC CMO USA, will join two other industry experts to discuss about small molecule drug development business trend, new technologies and future growth needs at the PBOA CMO/CDMO Theater.

Michael has more than 30 years of life sciences and pharmaceutical industry experiences working as biochemist, formulation scientist, sales, lab manager and head of operations.  He has worked for CMIC for over eight years, managing operations, technical service, engineering, warehouse and support site business growth needs. Before Joining CMIC, he has worked for 5 years at Catalent Pharma Solutions, responsible for oral solid formulation, process development and operations. Prior to Catalent, Michael also worked for BMS, Varian Inc, PharmaKinetics Laboratories, etc.

“CMIC CMO USA, Cranbury New Jersey site has more than 15 years history performing oral solid drug development and GMP manufacturing services for NDA and ANDA filings”, commented Yasuhiro Sejima, President of CMIC CMO USA, “We will continue to strive for innovation and supporting our pharmaceutical clients to help development better medicine sooner.”


> Learn more about CMIC Group.

> Learn more about CMIC CMO USA.